DRUG REPOSITIONING

WHY REPOSITION COMPOUNDS?

• Successfully repositioned drugs enter the market 3-5 years faster than a conventionally developed drug and as a consequence generate income sooner
• Success rates for repurposed drugs are higher and costs are lower than de novo R&D
• It is estimated that over 2,000 failed drugs are sitting on companies shelves and that this number grows at the rate of 150-200 drugs per year
• The science to evaluate new diseases continues to evolve so that science led repurposing (rather than random screening) is a viable business model
• Repositioning is expected to generate up to $20 billion in annual sales in 2012

WHY PARTNER WITH THOMSON REUTERS?

• Our unparallel access to chemical and biological data make us the best partner to assist your repurposing efforts
• Biological and chemical specialists can assist clients in identifying company assets for repositioning using both Thomson Reuters data along with your internal efforts
• Our drug repositioning service offers cost effective, accurate, and timely insights to identify repurposing opportunities that can expand revenue streams, decrease R&D cycle times, and improve R&D success

THE THOMSON REUTERS APPROACH TO DRUG REPOSITIONING

The Thomson Reuters Cortellis™ Professional Services team includes highly experienced drug hunters and experts in biology, chemistry, translational medicine, and portfolio analysis. Working with you, our team will deliver a customized, multi-disciplined approach to drug repositioning for your organization. Employing our proprietary content in harmony with your in-house data, we will evaluate opportunities using three main methods to help you reposition compounds:

• Drug focus - Structure similarity based methods can identify new indications to help exploit the full value of a drug
• Target focus - Using pathway analysis and protein structure to find new therapeutic uses for the library of drugs that modulate a particular mechanistic target or pathway
• Disease focus - Finding new approaches to drug intervention in a disease (or disease sub-population) and identifying available candidates

SELECTED CASE STUDIES

• Identified new targets and compounds to reposition existing drugs as treatment for Cystic Fibrosis
• Identified new targets and existing compounds for a major pharmaceutical company to reposition existing drugs for new disease area

FOR MORE INFORMATION

Visit cortellis.thomsonreuters.com/discover_cortellis/drug_repositioning or contact Thomson Reuters

THOMSON REUTERS AND CLIENT VALIDIFIED DATA SOURCES

OFF-LABEL USE SIDE EFFECTS CONTRA-INDICATIONS EXISTING DRUGS

DIAGNOSTICS BIOMARKERS ANIMAL MODELS

PATHWAYS IN-VITRO ASSAYS IN-VIVO ASSAYS MECHANISM OF ACTION

EFFICACY SAFETY OFF-TARGET EFFECTS IP

Drug repositioning can be approached from any combination of drug, disease and target aspects

THOMSON REUTERS REGIONAL OFFICES

North America
Philadelphia +1 800 336 4474
+1 215 386 0100

Latin America
+55 11 8370 9845

Europe, Middle East and Africa
Barcelona +34 93 459 2200
London +44 20 7433 4000

Asia Pacific
Singapore +65 6775 5088
Tokyo +81 3 5218 6500

For a complete office list visit: ip-science.thomsonreuters.com/contact

LS – 201207 – SER – DR
Copyright © 2012 Thomson Reuters